person · Reporting owner

Aghion Daniel

Disclosed activity across 1 company

Tapewire entity: 70620
SEC CIK: 0002004805

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ORAMED PHARMACEUTICALS INC.ORMP · Entity 6311	Director	December 31, 2025	January 03, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ORAMED PHARMACEUTICALS INC.

Report date December 31, 2025 · Filed January 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	113,441	Ending reported balance After 2025-12-31 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2025-12-31 · Grant · Acquired 30,000 · Balance 107,191 F1: Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in three annual tranches beginning January 1, 2027. Each RSU represents the right to receive one share of common stock, par value $0.012 per share ("Common Stock"), of the Issuer. Row 2 · 2025-12-31 · Grant · Acquired 6,250 · Balance 113,441 F2: Represents RSUs. The RSUs will vest in quarterly installments over a one-year period starting April 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in three annual tranches beginning January 1, 2027. Each RSU represents the right to receive one share of common stock, par value $0.012 per share ("Common Stock"), of the Issuer.

F2: Represents RSUs. The RSUs will vest in quarterly installments over a one-year period starting April 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 31, 2025 Filed Jan 3, 2026 01:02 UTC	ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311	GrantCommon Stock	6,250	Not disclosed	Not disclosed	Disclosure SEC source: 0001213900-26-000661 · ownership.xml · nonDerivative · entry 2 Aghion Daniel · CIK 0002004805 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,441 F2 · shares: Represents RSUs. The RSUs will vest in quarterly installments over a one-year period starting April 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer. F2 · price: Represents RSUs. The RSUs will vest in quarterly installments over a one-year period starting April 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer. Read SEC document
December 31, 2025 Filed Jan 3, 2026 01:02 UTC	ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311	GrantCommon Stock	30,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001213900-26-000661 · ownership.xml · nonDerivative · entry 1 Aghion Daniel · CIK 0002004805 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,191 F1 · shares: Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in three annual tranches beginning January 1, 2027. Each RSU represents the right to receive one share of common stock, par value $0.012 per share ("Common Stock"), of the Issuer. F1 · price: Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in three annual tranches beginning January 1, 2027. Each RSU represents the right to receive one share of common stock, par value $0.012 per share ("Common Stock"), of the Issuer. Read SEC document
June 05, 2025 Filed Jun 9, 2025 20:08 UTC	ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311	GrantCommon Stock	8,371	Not disclosed	Not disclosed	Disclosure SEC source: 0001213900-25-052623 · ownership.xml · nonDerivative · entry 2 Aghion Daniel · CIK 0002004805 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,191 F2 · price: Represents RSUs that will vest in equal installments as follows: on grant, July 1, 2025, October 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document
June 05, 2025 Filed Jun 9, 2025 20:08 UTC	ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311	GrantCommon Stock	30,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001213900-25-052623 · ownership.xml · nonDerivative · entry 1 Aghion Daniel · CIK 0002004805 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,820 F1 · price: . Represents Restricted Stock Units ("RSUs") that will vest in equal portions of 10,000 as follows: January 1, 2026, January 1, 2027 and January 1, 2028. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document
January 30, 2024 Filed Jan 30, 2024 22:30 UTC	ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311	GrantCommon Stock	3,750	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-24-002429 · doc4.xml · nonDerivative · entry 1 Aghion Daniel · CIK 0002004805 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,820 F1 · price: Represents Restricted Stock Units ("RSUs") that will vest in quarterly installments of approximately 937 on April 1, 2024, July 1, 2024, October 1, 2024 and January 1, 2025. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document
January 04, 2024 Filed Jan 8, 2024 21:33 UTC	ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311	GrantCommon Stock	5,070	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-24-001135 · doc4.xml · nonDerivative · entry 2 Aghion Daniel · CIK 0002004805 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,070 F2 · price: Represents Restricted Stock Units ("RSUs") that will vest in quarterly installments of approximately 1,267 on April 1, 2024, July 1, 2024, October 1, 2024 and January 1, 2025. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document
January 04, 2024 Filed Jan 8, 2024 21:33 UTC	ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311	GrantCommon Stock	30,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-24-001135 · doc4.xml · nonDerivative · entry 1 Aghion Daniel · CIK 0002004805 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 F1 · price: Represents Restricted Stock Units ("RSUs") that will vest in 3 installments as follows: 10,000 shall vest on each of January 1, 2025, January 1, 2026 and January 1, 2027. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.